NEW YORK, July 8 (GenomeWeb News) - Atugen said this week that it has signed a contract research agreement with Eisai London Research Laboratories, a subsidiary of Japanese drug maker Eisai.
Under the deal, Atugen will use its gene-silencing technologies to validate and optimize undisclosed drug targets provided by Eisai. Additional terms, including the financials, were not disclosed.
This is Atugen's second research agreement this year with a Japanese pharmaceutical company. The company also announced a multi-year agreement with Sankyo on May 17.